JP2020518276A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518276A5 JP2020518276A5 JP2019561141A JP2019561141A JP2020518276A5 JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5 JP 2019561141 A JP2019561141 A JP 2019561141A JP 2019561141 A JP2019561141 A JP 2019561141A JP 2020518276 A5 JP2020518276 A5 JP 2020518276A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- human
- nuclease
- nucleic acid
- engineered
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 10
- 101710163270 Nuclease Proteins 0.000 claims 9
- 238000000034 method Methods 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 102000015736 beta 2-Microglobulin Human genes 0.000 claims 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108091008874 T cell receptors Proteins 0.000 claims 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 2
- 238000003776 cleavage reaction Methods 0.000 claims 2
- 230000007017 scission Effects 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- 241000972680 Adeno-associated virus - 6 Species 0.000 claims 1
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 241000702421 Dependoparvovirus Species 0.000 claims 1
- 230000002759 chromosomal effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000006801 homologous recombination Effects 0.000 claims 1
- 238000002744 homologous recombination Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000002452 interceptive effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022175346A JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762503060P | 2017-05-08 | 2017-05-08 | |
| US62/503,060 | 2017-05-08 | ||
| US201762579460P | 2017-10-31 | 2017-10-31 | |
| US62/579,460 | 2017-10-31 | ||
| PCT/US2018/031674 WO2018208837A1 (en) | 2017-05-08 | 2018-05-08 | Nucleic acid molecules encoding an engineered antigen receptor and an inhibitory nucleic acid molecule and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Division JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020518276A JP2020518276A (ja) | 2020-06-25 |
| JP2020518276A5 true JP2020518276A5 (OSRAM) | 2021-06-10 |
| JP7170666B2 JP7170666B2 (ja) | 2022-11-14 |
Family
ID=62555183
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561141A Active JP7170666B2 (ja) | 2017-05-08 | 2018-05-08 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022175346A Pending JP2023022005A (ja) | 2017-05-08 | 2022-11-01 | 操作された抗原受容体をコードする核酸分子及び阻害性核酸分子、並びにそれらの使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US10745665B2 (OSRAM) |
| EP (2) | EP3634493A1 (OSRAM) |
| JP (2) | JP7170666B2 (OSRAM) |
| AU (1) | AU2018266698A1 (OSRAM) |
| CA (1) | CA3062698A1 (OSRAM) |
| WO (1) | WO2018208837A1 (OSRAM) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200190541A1 (en) * | 2017-04-28 | 2020-06-18 | Precision Biosciences, Inc. | Methods for reducing dna-induced cytotoxicity and enhancing gene editing in primary cells |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| MA52656A (fr) * | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées |
| WO2020112860A1 (en) * | 2018-11-30 | 2020-06-04 | Intima Bioscience, Inc. | Methods of identifying immunomodulatory genes |
| IL299249B2 (en) * | 2019-04-03 | 2024-01-01 | Prec Biosciences Inc | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) |
| WO2020254528A1 (en) * | 2019-06-18 | 2020-12-24 | Celyad Oncology S.A. | Cd52-deficient cells for adoptive cell therapy |
| US12016883B2 (en) * | 2019-09-26 | 2024-06-25 | Nantbio, Inc. | Primary T-cell expansion |
| IL297489A (en) * | 2020-04-23 | 2022-12-01 | Aztherapies Inc | Cellular ablation of hla-class i mhc |
| GB202006587D0 (en) * | 2020-05-04 | 2020-06-17 | Celyad S A | Improved scaffolds for multiplexed inhibitory rna |
| KR20230089570A (ko) * | 2020-10-26 | 2023-06-20 | 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 | 키메라 항원 수용체 (car) nk 세포 및 이의 용도 |
| KR20230130635A (ko) | 2020-12-11 | 2023-09-12 | 인텔리아 테라퓨틱스, 인크. | 세포에서 mhc 클래스 ii를 감소시키기 위한 조성물및 방법 |
| WO2022140586A2 (en) | 2020-12-23 | 2022-06-30 | Intellia Therapeutics, Inc. | Compositions and methods for reducing hla-a in a cell |
| AU2021410751A1 (en) | 2020-12-23 | 2023-07-13 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying ciita in a cell |
| JP2024502036A (ja) | 2020-12-30 | 2024-01-17 | インテリア セラピューティクス，インコーポレイテッド | 操作されたｔ細胞 |
| US20250127811A1 (en) | 2021-01-28 | 2025-04-24 | Precision Biosciences, Inc. | Modulation of tgf beta signaling in genetically-modified eukaryotic cells |
| CN117042794A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的t细胞免疫球蛋白和粘蛋白结构域3(tim3)组合物和方法 |
| EP4288525A1 (en) | 2021-02-08 | 2023-12-13 | Intellia Therapeutics, Inc. | Natural killer cell receptor 2b4 compositions and methods for immunotherapy |
| CN117042793A (zh) | 2021-02-08 | 2023-11-10 | 因特利亚治疗公司 | 用于免疫疗法的淋巴细胞活化基因3(lag3)组合物和方法 |
| MX2023015153A (es) * | 2021-07-01 | 2024-04-16 | Ningbo T Maximum Biopharmaceuticals Co Ltd | Polipéptido de unión a antígeno que se dirige a b7h3 y aplicación del mismo. |
| EP4392060A1 (en) | 2021-08-24 | 2024-07-03 | Intellia Therapeutics, Inc. | Programmed cell death protein 1 (pd1) compositions and methods for cell-based therapy |
| US20250302874A1 (en) | 2021-11-03 | 2025-10-02 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| CA3259337A1 (en) | 2022-06-16 | 2023-12-21 | Intellia Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR REDUCING MHC CLASS I IN A CELL |
| KR20250029125A (ko) | 2022-06-29 | 2025-03-04 | 인텔리아 테라퓨틱스, 인크. | 조작된 t 세포 |
| TW202503051A (zh) | 2023-03-07 | 2025-01-16 | 美商英特利亞醫療公司 | 用於免疫療法之ｃｉｓｈ組合物及方法 |
| WO2025038637A1 (en) | 2023-08-14 | 2025-02-20 | Intellia Therapeutics, Inc. | Compositions and methods for genetically modifying transforming growth factor beta receptor type 2 (tgfβr2) |
| TW202515992A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對轉形生長因子β受體２型（ＴＧＦβＲ２）進行基因修飾之組合物及方法 |
| TW202515994A (zh) | 2023-08-14 | 2025-04-16 | 美商英特利亞醫療公司 | 用於對ｃｄ７０進行基因修飾之組合物及方法 |
| WO2025137439A2 (en) | 2023-12-20 | 2025-06-26 | Intellia Therapeutics, Inc. | Engineered t cells |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| CA2681922C (en) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Ｄｎａ認識のための結合タンパク質におけるまたはそれに関連する改良 |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| WO2001029058A1 (en) | 1999-10-15 | 2001-04-26 | University Of Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| US6326193B1 (en) | 1999-11-05 | 2001-12-04 | Cambria Biosciences, Llc | Insect control agent |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
| WO2001096584A2 (en) | 2000-06-12 | 2001-12-20 | Akkadix Corporation | Materials and methods for the control of nematodes |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| EP1476547B1 (en) | 2002-01-23 | 2006-12-06 | The University of Utah Research Foundation | Targeted chromosomal mutagenesis using zinc finger nucleases |
| AU2003218382B2 (en) | 2002-03-21 | 2007-12-13 | Sangamo Therapeutics, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| EP1581610A4 (en) | 2002-09-05 | 2009-05-27 | California Inst Of Techn | USE OF CHIMERIC NUCLEASES TO STIMULATE GEN-TARGETING |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| WO2007014275A2 (en) | 2005-07-26 | 2007-02-01 | Sangamo Biosciences, Inc. | Targeted integration and expression of exogenous nucleic acid sequences |
| US20070036773A1 (en) * | 2005-08-09 | 2007-02-15 | City Of Hope | Generation and application of universal T cells for B-ALL |
| ES2602184T3 (es) | 2005-10-18 | 2017-02-20 | Precision Biosciences | Meganucleasas diseñadas racionalmente con especificidad de secuencia y afinidad de unión a ADN alteradas |
| EP2215223B1 (en) | 2007-10-31 | 2013-05-01 | Precision Biosciences, Inc. | Rationally-designed single-chain meganucleases with non-palindromic recognition sequences |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| NO2510096T3 (OSRAM) | 2009-12-10 | 2015-03-21 | ||
| KR101982360B1 (ko) | 2011-04-05 | 2019-05-24 | 셀렉티스 | 콤팩트 tale-뉴클레아제의 발생 방법 및 이의 용도 |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| ES2782125T3 (es) | 2014-03-11 | 2020-09-10 | Cellectis | Método para generar linfocitos T compatibles para trasplante alogénico |
| AU2015339743C1 (en) * | 2014-10-31 | 2021-04-22 | The Trustees Of The University Of Pennsylvania | Altering gene expression in modified T cells and uses thereof |
| BR112017020750A2 (pt) * | 2015-03-27 | 2018-06-26 | Harvard College | células t modificadas e métodos de produção e utilização das mesmas |
| AU2016271147B2 (en) * | 2015-05-29 | 2022-09-08 | Juno Therapeutics, Inc. | Composition and methods for regulating inhibitory interactions in genetically engineered cells |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| AU2016333898B2 (en) | 2015-10-05 | 2020-11-12 | Precision Biosciences, Inc. | Genetically-modified cells comprising a modified human T cell receptor alpha constant region gene |
| WO2017112859A1 (en) * | 2015-12-23 | 2017-06-29 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| CN109311984A (zh) * | 2016-03-11 | 2019-02-05 | 蓝鸟生物公司 | 基因组编辑的免疫效应细胞 |
-
2018
- 2018-05-08 WO PCT/US2018/031674 patent/WO2018208837A1/en not_active Ceased
- 2018-05-08 AU AU2018266698A patent/AU2018266698A1/en not_active Abandoned
- 2018-05-08 EP EP18729846.8A patent/EP3634493A1/en not_active Withdrawn
- 2018-05-08 JP JP2019561141A patent/JP7170666B2/ja active Active
- 2018-05-08 CA CA3062698A patent/CA3062698A1/en active Pending
- 2018-05-08 EP EP21209275.3A patent/EP4029943A1/en active Pending
-
2019
- 2019-11-08 US US16/678,600 patent/US10745665B2/en active Active
-
2020
- 2020-07-13 US US16/927,452 patent/US20200339952A1/en not_active Abandoned
-
2022
- 2022-04-04 US US17/712,864 patent/US20220228115A1/en active Pending
- 2022-11-01 JP JP2022175346A patent/JP2023022005A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518276A5 (OSRAM) | ||
| Lei et al. | Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy | |
| JP7379447B2 (ja) | ゲノム編集分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| JP2025013884A5 (OSRAM) | ||
| CN114736901B (zh) | 用于减少pd-l1表达的寡核苷酸 | |
| JP2019522461A5 (OSRAM) | ||
| JP2018534950A5 (OSRAM) | ||
| JP2016538885A5 (OSRAM) | ||
| JP2021518102A (ja) | 異常ヘモグロビン症の治療のためのシステム及び方法 | |
| CN112930395A (zh) | 靶向rna的融合蛋白组合物和使用方法 | |
| JP2018522072A5 (OSRAM) | ||
| JP2017512767A5 (OSRAM) | ||
| JP2020524998A5 (OSRAM) | ||
| JP2011004753A5 (OSRAM) | ||
| JP2010273685A5 (OSRAM) | ||
| CN116083487A (zh) | 用于治疗遗传病状的方法和组合物 | |
| RU2013152648A (ru) | Аденовирус обезьян и гибридные аденовирусные векторы | |
| JP2019524140A5 (OSRAM) | ||
| JP2013509168A5 (OSRAM) | ||
| JP2017524348A5 (OSRAM) | ||
| JP2022509017A (ja) | 抗ｐｔｋ７免疫細胞癌療法 | |
| IL316189A (en) | Treatment of complement-mediated disorders | |
| JP2020517270A5 (OSRAM) | ||
| JP2015524413A5 (OSRAM) | ||
| JP2016513457A5 (OSRAM) |